Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study

(2020) Jian Wu et al.   CLINICAL INFECTIOUS DISEASES

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China

(2020) Dawei Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series

(2020) Achille Aouba et al.   ANNALS OF THE RHEUMATIC DISEASES

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

(2020) George Dimopoulos et al.   Cell Host & Microbe

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

(2020) Fei Zhou et al.   LANCET

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

On the Alert for Cytokine Storm: Immunopathology in COVID ‐19

(2020) Lauren A. Henderson et al.   Arthritis & Rheumatology

A minimal common outcome measure set for COVID-19 clinical research

(2020) John C Marshall et al.   LANCET INFECTIOUS DISEASES

An inflammatory cytokine signature predicts COVID-19 severity and survival

(2020) Diane Marie Del Valle et al.   NATURE MEDICINE

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

(2019) Esraa M. Eloseily et al.   Arthritis & Rheumatology

Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis

(2017) Philipp Wohlfarth et al.   JOURNAL OF INTENSIVE CARE MEDICINE

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome

(2016) Bita Shakoory et al.   CRITICAL CARE MEDICINE

Therapeutic Role of Anakinra, an Interleukin-1 Receptor Antagonist, in the Management of Secondary Hemophagocytic Lymphohistiocytosis/Sepsis/Multiple Organ Dysfunction/Macrophage Activating Syndrome in Critically Ill Children*

(2014) Surender Rajasekaran et al.   Pediatric Critical Care Medicine